United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

"This is a vaccine that was developed without cutting corners from a company with 171 years of credentials," Pfizer CEO Albert Bourla said.

Pfizer's CEO hasn't gotten his Covid vaccine yet, saying he doesn't want to cut in line

Pfizer and the U.S. are working out details on timing, CEO Albert Bourla told CNBC's "Squawk Box" in an interview.

Pfizer negotiating with U.S. to provide an additional 100 million Covid vaccine doses, CEO says

"This has been a challenging process because there have been multiple conversations happening as recently as November," Dr. Scott Gottlieb told CNBC.

U.S. could have bought additional Pfizer vaccines in November but passed, says Pfizer board member

FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.

COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod

Moderna

US drugmakers Pfizer and Moderna could rake in around $32 billion in revenues from their COVID-19 vaccines in 2021, according to Wall Street estimates. Pfizer and its German partner BioNTech will bring in roughly $19 billion from global sales of its COVID-19 vaccine in 2021, according to Morgan Stanley estimates first reported by CNN on Friday.

Pfizer and Moderna could earn $32 billion in revenues from their COVID-19 vaccines in 2021

Pfizer CEO Albert Bourla on Monday said the company has not signed an agreement yet with the United States on providing 100 million more coronavirus vaccine doses in 2021, telling CNN it is still negotiating whether to deliver the drug in the second or third quarter of the year.

Pfizer CEO says still negotiating with U.S. on more coronavirus vaccines

Pfizer Inc. and its Germany-based partner BioNTech SE said overall results of a Phase 1/2 study in Germany of its COVID-19 vaccine candidate, BNT162b2, mirrored those from the U.S. study. The companies said the results supported "the favorable safety profile and robust induction of virus-specific antibody responses.

Pfizer, BioNTech COVID-19 vaccine candidate study in Germany support safety profile

Abbott Labs

Novavax

These coronavirus leaders are great picks for different reasons.

3 COVID Stocks That Are Screaming Buys

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) plan to allow the participants in the COVID-19 vaccine trials to learn if they were part of the placebo group and offer them free shots, Bloomberg reports. What Happened: Pfizer, in an emailed statement to Bloomberg, said that both companies are providing voluntary options to COVID-19 vaccine clinical trial volunteers, who were part of the placebo group, to receive the vaccine at scheduled time points.

Pfizer Plans To Offer COVID-19 Vaccine To Placebo Group Trial Volunteers: Report

Hint: It's a big number -- but not nearly big enough.

How Many COVID Vaccine Doses Will Pfizer and Moderna Distribute by Year-End?

Centers for Disease Control and Prevention Director Dr. Robert Redfield said Sunday that he signed the CDC's official recommendation for Americans 16 and older to use the Pfizer-BioNTech coronavirus vaccine and applauded the vaccine as a step to "help restore some normalcy to our lives and our country.".

CDC's Redfield officially recommends Pfizer coronavirus vaccine

FedEx

FedEx Express (NYSE: FDX)  and UPS (NYSE: UPS) trucks departed Pfizer Inc.'s (NYSE: PFE) sprawling manufacturing facility in Portage, Michigan, on Sunday morning loaded with COVID-19 vaccines packed in dry ice to maintain them at ultra-cold temperatures. The express delivery companies have roughly divided the nation in two, with FedEx supplying the western states and UPS those in the east, based on plans developed in coordination with the federal government's Operation Warp Speed.

FedEX, UPS trucks depart with first Pfizer COVID vaccines

Arcturus Therapeutics

The first to market won't necessarily dominate the market over the long run.

These 2 Early-Stage COVID Vaccines Could Be Game-Changers

Johnson & Johnson

Vaxart

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

COVID Vaccine Stock Ideas for Different Investors

CVS Health

Walgreens

How Soon Will COVID Vaccines Be Available After FDA Authorization?

The first trucks carrying a COVID-19 vaccine for widespread use in the United States are set to pull out of a Michigan manufacturing plant Sunday.

Pfizer begins packing coronavirus vaccine shipments at Michigan facility

There's something for every kind of investor with this list.

3 Top Coronavirus Stocks to Buy in December

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of the Pfizer-BioNTech COVID-19 vaccine in people 16 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). This ACIP vote follows the December 1, 2020, ACIP recommend

U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older

The Advisory Committee on Immunization Practices, part of the Centers for Disease Control and Prevention, just voted to recommend Pfizer's coronavirus vaccine for everyone over age 16. The move further paves the way for the shots to be rolled out in the US, although CDC Director Robert Redfield still must accept the panel's recommendation.

A CDC panel just voted to recommend Pfizer's COVID-19 shot for people 16 years and older

The FDA just cleared the first Covid vaccine for emergency use. Within hours, FedEx and UPS will begin shipping 2.9 million doses across the country.

Pfizer's Covid vaccine ships within hours. Here's how the U.S. plans to get it to everyone

A key U.S. Centers for Disease Control and Prevention panel voted unanimously to recommend Pfizer-BioNTech's Covid-19 vaccine for people 16 years and older on Saturday.

CDC panel clears Pfizer Covid vaccine for people 16 years and older, clearing another pivotal hurdle

The vaccines are already being packaged, an official said.

Pfizer Covid Vaccine Expected To Arrive In All 50 States By Monday

Why the U.K. Beat the U.S. in Authorizing a COVID Vaccine

FDA Authorizes Pfizer and BioNTech's Coronavirus Vaccine

Pfizer Inc. (NYSE: PFE) received emergency use authorisation from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine that it developed in collaboration with Germany's BioNTech on Friday. The first round of vaccination comprising 2.9 million doses will begin in the upcoming week and focus primarily on elderly patients and healthcare workers this month.

News for Pfizer Stock (PFE)